AbbVie is making good on its plans to search for new mechanisms of action, this time with French biotech OSE Immunotherapeutics for a monoclonal antibody targeting inflammation.
AbbVie will pay $48 million upfront to OSE for an exclusive global license to develop, manufacture and commercialize the antibody, dubbed OSE-230. OSE is eligible for another $665 million in milestones as well as tiered royalties on global net sales.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.